Enhertu as Second-Line Therapy for HER2-Positive Advanced Gastric Cancer
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
On September 18, 2021, AstraZeneca announced the results of the DESTINY-Gastric02 Phase 2 clinical trial, evaluating Enhertu (Trastuzumab deruxtecan) as a second-line therapy for patients with HER2-positive advanced gastric cancer. The findings were presented at the ESMO Congress 2021.
Study Design: DESTINY-Gastric02 Trial
DESTINY-Gastric02 is an international, multicenter, open-label, single-arm Phase 2 trial. It enrolled patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) cancer who had progressed on or after a trastuzumab-containing regimen.
Patients received Enhertu at a dose of 6.4 mg/kg every three weeks. The primary endpoint was objective response rate (ORR).
Key Efficacy Results (Median Follow-up 5.7 Months)
- Objective Response Rate (ORR): 38.0%
- Complete Response (CR): 3.8%
- Partial Response (PR): 34.2%
- Disease Control Rate (DCR): 81.0%
- Median Duration of Response (DOR): 8.1 months
- Median Progression-Free Survival (PFS): 5.5 months
Safety Profile
The safety profile was consistent with previous trials of Enhertu. The most common Grade 3 or higher adverse events included:
- Anemia: 7.6%
- Neutropenia: 7.6%
- Interstitial Lung Disease (ILD): 7.6% (N=6 patients)
- Nausea and Fatigue: 3.8% each
Most adverse events were Grade 1 or 2.
Conclusion
Dr. Eric Van Cutsem from University Hospitals Leuven concluded that Enhertu demonstrates a clinically meaningful response in patients with HER2-positive advanced gastric cancer who have failed prior treatment, establishing its role as a potent second-line option.
Source: AstraZeneca Press Release - DESTINY-Gastric02 Results
#GastricCancer #HER2Positive #Enhertu #TDXd #DESTINYGastric02 #CancerResearch
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4